Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

References

• Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Nathan DM Cleary PA Backlund JY Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Handelsman Y Bloomgarden ZT Grunberger G American Association of Clinical Endocrinologists and American College of Endocrinology: Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015 Endocr Pract 2015 21 Suppl 1 1 87 25869408
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015 – a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Peyrot M Barnett AH Meneghini LF Schumm-Draeger PM Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study Diabet Med 2012 29 5 682 689 22313123
   PubMed Web of Science ®Google Scholar
• Peyrot M Rubin RR Lauritzen T Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 2005 28 11 2673 2679 16249538
   PubMed Web of Science ®Google Scholar
• Edelman S Pettus J Challenges associated with insulin therapy in type 2 diabetes mellitus Am J Med 2014 127 10 Suppl S11 S16 25282008
   PubMed Web of Science ®Google Scholar
• Pettus J Cavaiola TC Tamborlane WV Edelman S The past, present, and future of basal insulins Diabetes Metab Res Rev 2016 32 6 478 496 26509843
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Rønn BB Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 2004 53 6 1614 1620 15161770
   PubMed Web of Science ®Google Scholar
• Lepore M Pampanelli S Fanelli C Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 2000 49 12 2142 2148 11118018
   PubMed Web of Science ®Google Scholar
• Evans M Schumm-Draeger PM Vora J King AB A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations Diabetes Obes Metab 2011 13 8 677 684 21410860
   PubMed Web of Science ®Google Scholar
• Little S Shaw J Home P Hypoglycemia rates with basal insulin analogs Diabetes Technol Ther 2011 13 Suppl 1 S53 S64 21668338
   PubMed Web of Science ®Google Scholar
• Barnett AH Insulin glargine in the treatment of type 1 and type 2 diabetes Vasc Health Risk Manag 2006 2 1 59 67 17319470
   PubMedGoogle Scholar
• Poon K King AB Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs Drug Healthc Patient Saf 2010 2 213 223 21701633
   PubMedGoogle Scholar
• Heinemann L Linkeschova R Rave K Hompesch B Sedlak M Heise T Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 2000 23 5 644 649 10834424
   PubMed Web of Science ®Google Scholar
• Riddle MC Rosenstock J Gerich J The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003 26 11 3080 3086 14578243
   PubMed Web of Science ®Google Scholar
• Rosenstock J Dailey G Massi-Benedetti M Fritsche A Lin Z Salzman A Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 2005 28 4 950 955 15793205
   PubMed Web of Science ®Google Scholar
• Geller AI Shehab N Lovegrove MC National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations JAMA Intern Med 2014 174 5 678 686 24615164
   PubMed Web of Science ®Google Scholar
• Bron M Marynchenko M Yang H Yu AP Wu EQ Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs Postgrad Med 2012 124 1 124 132
   PubMed Web of Science ®Google Scholar
• Bruderer SG Bodmer M Jick SS Bader G Schlienger RG Meier CR Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK: a nested case-control analysis Diabetes Obes Metab 2014 16 9 801 811 24612200
   PubMed Web of Science ®Google Scholar
• Moen MF Zhan M Hsu VD Frequency of hypoglycemia and its significance in chronic kidney disease Clin J Am Soc Nephrol 2009 4 6 1121 1127 19423569
   PubMed Web of Science ®Google Scholar
• Davis TM Brown SG Jacobs IG Bulsara M Bruce DG Davis WA Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study J Clin Endocrinol Metab 2010 95 5 2240 2247 20305006
   PubMed Web of Science ®Google Scholar
• Steinstraesser A Schmidt R Bergmann K Dahmen R Becker RH Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml Diabetes Obes Metab 2014 16 9 873 876 24571126
   PubMed Web of Science ®Google Scholar
• Becker RH Dahmen R Bergmann K Lehmann A Jax T Heise T New insulin glargine 300 units·mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units·mL−1 Diabetes Care 2015 38 4 637 643 25150159
   PubMed Web of Science ®Google Scholar
• Becker RH Nowotny I Teichert L Bergmann K Kapitza C Low within- and between-day variability in exposure to new insulin glargine 300 U/ml Diabetes Obes Metab 2015 17 3 261 267 25425394
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis Lantus [prescribing information] 2015 Available from: http://products.sanofi.us/lantus/lantus.pdf Accessed April 29, 2017
   Google Scholar
• Bergenstal RM Bailey TS Rodbard D Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) Diabetologia 2014 57 1 Suppl S388 S389
   Google Scholar
• Shiramoto M Eto T Irie S Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes Diabetes Obes Metab 2015 17 3 254 260 25425297
   PubMed Web of Science ®Google Scholar
• Bolli GB Riddle MC Bergenstal RM New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) Diabetes Obes Metab 2015 17 4 386 394 25641260
   PubMed Web of Science ®Google Scholar
• Home PD Bergenstal RM Bolli GB New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3A, open-label clinical trial (EDITION 4) Diabetes Care 2015 38 12 2217 2225 26084341
   PubMed Web of Science ®Google Scholar
• Matsuhisa M Koyama M Cheng X New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP1) Diabetes Obes Metab 2016 18 4 375 383 26662964
   PubMed Web of Science ®Google Scholar
• Riddle MC Bolli GB Ziemen M New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care 2014 37 10 2755 2762 25078900
   PubMed Web of Science ®Google Scholar
• Terauchi Y Koyama M Cheng X New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2) Diabetes Obes Metab 2016 18 4 366 374 26662838
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H Bergenstal R Ziemen M New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care 2014 37 12 3235 3243 25193531
   PubMed Web of Science ®Google Scholar
• Riddle MC Yki-Järvinen H Bolli GB One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension Diabetes Obes Metab 2015 17 9 835 842 25846721
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H Bergenstal RM Bolli GB Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension Diabetes Obes Metab 2015 17 12 1142 1149 26172084
   PubMed Web of Science ®Google Scholar
• Matsuhisa M Koyama M Cheng X Shimizu S Hirose T Sustained glycaemic control and less nocturnal hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml over 1 year in Japanese people with type 1 diabetes mellitus (EDITION JP 1) Diabetologia 2015 58 1 Suppl S2 S3
   Google Scholar
• Ritzel R Roussel R Bolli GB Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes Diabetes Obes Metab 2015 17 9 859 867 25929311
   PubMed Web of Science ®Google Scholar
• Ritzel R Roussel R Giaccari A Patient-level meta-analysis of 1y phase 3A EDITION type 2 diabetes mellitus studies: glycaemic control and hypoglycaemia with insulin glargine 300 U/ml (Gla-300) vs glargine 100 U/ml (Gla-100) Diabetologia 2015 58 1 Suppl S472
   Google Scholar
• Terauchi Y Koyama M Cheng X Sumi M Hirose T Sustained glycaemic control and less hypoglycaemia over1y with new insulin glargine 300 U/ml vs glargine 100 U/ml in Japanese type 2 diabetes mellitus people on basal insulin + OAD(s) (EDITION JP 2) [abstract 959] Diabetologia 2015 58 1 Suppl S463
   Google Scholar
• No authors listed Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 2005 28 5 1245 1249 15855602
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis Toujeo [prescribing information] 2015 Available from: http://products.sanofi.us/toujeo/toujeo.pdf Accessed April 29, 2017
   Google Scholar
• Riddle MC Bolli GB Home PD Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in People with type 2 diabetes Diabetes Technol Ther 2016 18 4 252 257 26840338
   PubMed Web of Science ®Google Scholar
• Goto A Goto M Terauchi Y Yamaguchi N Noda M Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes J Am Heart Assoc 2016 4 3 e002875
   Google Scholar
• Hsu PF Sung SH Cheng HM Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study Diabetes Care 2013 36 4 894 900 23223349
   PubMed Web of Science ®Google Scholar
• Gerstein HC Bosch J Dagenais GR Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
   PubMed Web of Science ®Google Scholar
• Yale JF Aroda VR Charbonnel B Older people with type 2 diabetes: glycemic control and hypoglycemia risk with new insulin glargine 300 U/mL Diabetes 2015 64 Suppl 1 A261
   Google Scholar
• Sanofi Comparison of the safety and efficacy of HOE901-U300 with Lantus in older patients with type2 diabetes insufficiently controlled on their current antidiabetic medications (SENIOR) Available from: https://clinicaltrials.gov/ct2/show/NCT02320721. NLM identifier: NCT02320721 Accessed November 22, 2015
   Google Scholar
• Sanofi Study of two titration algorithms with insulin glargine 300 units/mL in type 2 diabetes mellitus patients (TITRATION) Available from: https://clinicaltrials.gov/ct2/show/NCT02401243. NLM identifier: NCT02401243 Accessed November 22, 2015
   Google Scholar
• Sanofi Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo (AUTOMATIX) Available from: https://clinicaltrials.gov/ct2/show/NCT02585674. NLM identifier: NCT02585674 Accessed March 14, 2016
   Google Scholar
• Roussel R D’Emden MC Fisher M Switching from twice-daily basal insulin to once-daily new insulin glargine 300 U/mL (Gla-300): an analysis in people with T2DM (EDITION 1 and 2) Diabetes 2015 64 1 Suppl A261
   Google Scholar
• Freemantle N Chou E Frois C Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis BMJ Open 2016 6 2 e009421
   Web of Science ®Google Scholar
• Sanofi A “real world” trial to determine efficacy and health outcomes of Toujeo (Achieve Control Real Life Study Program) Available from: https://clinicaltrials.gov/ct2/show/NCT02451137. NLM identifier: NCT02451137 Accessed November 24, 2015
   Google Scholar
• Klonoff D Nayberg I Erbstein F Cali A Brulle-Wohlhueter C Haak T Usability of the Gla-300 injection device compared with three other commercialized disposable insulin pens: results of an interview-based survey J Diabetes Sci Technol 2015 9 4 936 938 26002837
   PubMedGoogle Scholar
• Klonoff D Nayberg I Thonius M Accuracy and injection force of the Gla-300 injection device compared with other commercialized disposable insulin pens J Diabetes Sci Technol 2015 10 1 125 130 26311720
   PubMedGoogle Scholar
• Anderson BJ Redondo MJ What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol 2011 5 6 1563 1571 22226279
   PubMedGoogle Scholar
• Escalada J Halimi S Senior PA Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes (T2DM) and mild-to-moderate renal impairment Diabetes 2016 65 1 Suppl A18
   Google Scholar
• Fowler MJ Diabetes treatment, part 3: insulin and incretins Clin Diabetes 2008 26 1 35 39
   Google Scholar
• Novo Nordisk Levemir [prescribing information] 2015 Available from: http://www.novo-pi.com/levemir.pdf Accessed April 29, 2017
   Google Scholar
• Novo Nordisk Tresiba [prescribing information] 2015 Available from: http://www.novo-pi.com/tresiba.pdf Accessed April 29, 2017
   Google Scholar